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Rubella has been eliminated from the U.S. but remains endemic in some parts of the 
world. Given that vaccine uptake and effectiveness are below 100%, individuals in the 
U.S. may experience a non-zero risk of rubella infection, especially if they are to travel. 
This risk is particularly important for pregnant women since infection during pregnancy 
can result in adverse outcomes such as congenital rubella syndrome and fetal or neonatal 
death. Identifying socio-demographic groups at higher risk for susceptibility and 
quantifying country-specific risk of infection can help clinicians provide targeted 
recommendations regarding travel during pregnancy. 
Methods 
Using data from the 2009-2010 cycle of the National Health and Nutrition Examination 
Survey (NHANES), we evaluated overall prevalence of rubella susceptibility among 
women of reproductive age and in socio-demographic groups considered at highest risk 
for CRS as well as those most likely to travel during pregnancy. We also estimated the 
force of infection using a rubella transmission model to highlight areas to which prenatal 
travel may be inadvisable. 
Results 
Among 1,685 female NHANES participants aged 18-49 years in 2009-2010, prevalence 
of susceptibility to rubella, defined as an IgG ELISA result of <10 IU/mL, was 3.3%. 
Odds of susceptibility did not vary significantly by age, race/ethnicity, country of birth, 
citizenship status, or receipt of hepatitis A vaccine. Analysis of a subgroup of women 
 iii 
born outside of the U.S. showed no differences in susceptibility by length of time since 
moving to the U.S. 
 
Among 147 countries evaluated by our transmission model, 43 had forces of infection at 
or above one infection per thousand person years. Areas with the highest forces of 
infection were those to where travel is relatively infrequent. 
Conclusion 
This study is one of few studies evaluating susceptibility to rubella among women of 
reproductive age in the U.S. in the post-elimination era. Rubella burden remains 
considerable in some countries, and pregnant travelers to these areas may be at 
particularly high risk for prenatal infection. Further studies are needed with larger 
samples to adequately evaluate differences in susceptibility by demographic and other 
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Introduction 
Rubella is a contagious viral disease that was declared eliminated from the U.S. in 
2004 following dedicated and sustained efforts to induce population-level immunity 
through vaccination.1,2 Despite the widespread availability of rubella-containing vaccines 
(RCVs) in many parts of the world, the virus remains a leading cause of vaccine-
preventable birth defects worldwide.3 This circumstance is attributable to several factors 
including the absence in many countries of routine vaccination for rubella, spatial 
heterogeneity in vaccine coverage within countries employing RCVs,4 and migration or 
travel-associated rubella importation to areas where RCV coverage is below herd 
immunity thresholds.5,6 In addition, the vaccine is considered 97% effective after one 
dose,7 meaning some individuals remain susceptible despite having been vaccinated. 
Based on the continuing endemicity of rubella observed in countries outside of the 
Americas and susceptibility to infection due to a lack of or incomplete immunization, 
women in the U.S. and their fetuses may experience a non-zero risk of rubella infection 
and consequently fetal congenital rubella syndrome (CRS), particularly if they travel 
internationally during pregnancy. Furthermore, current clinical practices and guidelines 
in the U.S. may leave gaps in risk minimization related to rubella and CRS. Antibody 
titers to the virus are typically measured at a woman’s first prenatal visit in order to 
identify vulnerability to infection8 but the vaccine is contraindicated during pregnancy 
and risk avoidance counseling is not necessarily provided to women who are found to be 
serologically naïve.8  
Using data from NHANES 2009-2010, the objective of this study was to estimate 
overall susceptibility to rubella among women of childbearing age and to determine 
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whether women in this age group who are more likely than others to travel are at 
increased risk for non-immunity to rubella infection. In addition, we aimed to quantify a 
susceptible woman's likelihood of infection for various countries, as determined by 
country-level estimates of force of infection.  
Rubella and Congenital Rubella Syndrome 
Rubella has long been considered a disease of public health importance owing to 
its high level of infectiousness and its teratogenic effects on the gestating fetus. Postnatal 
transmission of the rubella virus occurs through the respiratory route, typically causing 
acute yet mild illness characterized by rash, low grade fever, and swollen lymph nodes 
appearing 2-3 weeks after initial exposure.9 As many as 30% of infections acquired 
postnatally are never clinically apparent.10 
Despite its relatively innocuous presentation in those acquiring infection 
postnatally, rubella causes substantial morbidity and mortality when expectant mothers 
are infected shortly before conception or in the first trimester of pregnancy.10,11 Because 
the virus can cross the placenta and infect the fetus, cause systemic inflammation, and 
hinder organ development,9,12 prenatal rubella infection can result in pregnancy loss, 
neonatal death, and other severe adverse outcomes. The fetus may be affected by 
congenital anomalies in up to 90% of maternal cases occurring in the first 11 weeks of 
pregnancy;11 the presence of which are known in a rubella-positive neonate as congenital 
rubella syndrome, or CRS. CRS most commonly manifests in the optic lens (e.g., as 
cataracts), heart (as patent ductus arteriosus or peripheral pulmonary artery stenosis), or 
cochlea (as hearing impairment)8 but can take other forms, as rubella has been shown to 
damage the brain, lung, liver, spleen, kidney, bone marrow, bones, and endocrine 
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organs.13 In addition to heart disease and vision or hearing loss, infants with a CRS 
diagnosis may experience a host of other pathologies including hepatosplenomegaly, 
microcephaly, encephalitis, and/or developmental delays.14 Throughout the globe, an 
estimated 100,000 infants are affected by CRS each year.15 
In the pre-vaccine era, rubella was known to circulate in a pattern marked by 
yearly seasonal epidemics, with larger epidemics occurring every 6-9 years.16 With this 
dynamic, most individuals susceptible at the start of a large epidemic would be infected 
by its end, resulting in an average age of infection of 9-11 years.17 However, the 
introduction of a rubella-containing vaccine in 1969 changed the dynamics of rubella 
throughout much of the world, leading to decreases in both the force of infection and the 
annual number of incident rubella and CRS cases. As a result of systematic vaccination 
of infants and a vaccine campaign targeted toward adolescent girls and adult women, the 
last U.S. rubella epidemic occurred in 1964; forty years later, rubella was declared 
eliminated from the country.10 In the meantime, other countries in the Western 
Hemisphere also scaled up rubella vaccination efforts in the interest of eliminating both 
rubella and CRS and consequently, the last known endemic case of rubella in the 
Americas occurred in Argentina in 2009. The WHO declared the virus eliminated from 
the region of the Americas in 2015.18 Globally, more than 80 countries have eliminated 
rubella since RCVs were introduced.18   
 Despite the substantial progress made with respect to reductions in rubella and 
CRS, the virus continues to circulate in areas with no or low RCV coverage; worldwide, 
an average of 30% of children do not have access to these vaccines.19 WHO has 
established recommendations for setting elimination goals for countries that have not 
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achieved rubella elimination,20 however, a country’s decision to implement these goals is 
not necessarily straightforward. With a vaccine effectiveness of 97%, it is estimated that 
depending on the birth rate in an area, between 77 and 87% of the population must be 
vaccinated from rubella in order to achieve local elimination.21,22 Reaching these levels of 
immunity can prove challenging in countries where resources are limited, healthcare 
infrastructure is weak, or there exists spatial or temporal variability in the proportion 
immune. 6,23 In addition, because increased vaccination leads to decreases in the force of 
infection and consequently increases in the average age of infection, the public health 
impact of rubella can be made worse for pregnant women if vaccine coverage is 
inadequate for eliminating transmission, but is high enough that infections are expected 
to occur during the childbearing years.24,25 
As of 2018, the WHO region of the Americas was the only of the six WHO 
regions to have achieved elimination,19 defined as the absence of sustained rubella 
transmission for a period of at least one year.26 The European and Western Pacific 
Regions have established elimination goals, while the South East Asia region has set a 
goal for rubella control.19 The remaining two regions, the Eastern Mediterranean and 
Africa, have not yet established such goals.19 In each of the two regions without goals for 
elimination or control, vaccine coverage remains below WHO’s recommended threshold 
of 80%.19 More specifically, in the African region, 27 (57%) countries have not added 
RCVs to their routine immunization schedules, and RCV coverage is low, at 32% for the 
region overall.19 In the Eastern Mediterranean Region, 16 (76%) countries have 
introduced RCVs, but vaccine coverage is estimated at only 45%. South East Asia has 
implemented routine use of RCVs in 10 (91%) countries, and vaccine coverage is close to 
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the recommended threshold, at 83%.19 Globally, a total of 26 countries have not 
introduced RCVs at all.3 In recent years, the highest rubella burden has occurred in Africa 
and South East Asia.15 As such, U.S. based travelers to these and other areas with low 
vaccine coverage may be at risk for infection and CRS.  
Travel Advisories During Pregnancy 
Travel advisories specific to pregnant women have been implemented by various 
health agencies for several infectious diseases over time. These advisories could play an 
important role in minimizing risk of rubella among pregnant women in the U.S., given 
that most known cases of rubella occurring in the U.S. since 2004 have been imported.27 
However, travel guidelines issued by these agencies do not currently provide guidance on 
travel to rubella-affected areas. 
In 2005, the International Health Regulations, an agreement made by the 196 
member countries of the WHO, established guidelines for maintaining global health 
security, including guidelines surrounding the implementation of recommendations for 
restricted travel.28 Specifically, the purpose of the agreement is to “prevent, protect 
against, control, and provide a public health response to the international spread of 
disease in ways that are commensurate with and restricted to public health risks,” while 
avoiding unnecessary restrictions on travel and trade. The scope of the agreement is not 
limited to any particular diseases, but is intended to cover any “illness or medical 
condition, irrespective of origin or source, that presents or could present significant harm 
to humans.”28 
In congruence with the requirements set forth by the IHR, the CDC publishes the 
U.S. government’s travel health guidelines29, which include pretravel health evaluation 
 6 
and destination-specific recommendations for pregnant travelers. At present, the CDC 
recommends that all pregnant women planning to travel are screened for immunity to 
rubella, though rubella susceptibility is not listed among its contraindications for travel.29  
Furthermore, though these guidelines emphasize risk of certain infectious diseases during 
travel (e.g., malaria, hepatitis A and E) and recommend against travel to Zika-affected 
areas, no emphasis is placed on risks related to rubella, despite the high probability of 
poor fetal outcomes among women experiencing infection early in pregnancy. 
The American College of Obstetricians and Gynecologists (ACOG) publishes 
clinical guidance on women’s health and pregnancy and issues recommendations to 
obstetricians for providing perinatal care. Testing recommendations for immunity to 
rubella during the first prenatal visit are included in their obstetrical practice guidelines, 
which typically occur during a woman’s first trimester of pregnancy.8 Under ACOG’s 
recommendations, pregnant women found to be non-immune to rubella should be 
vaccinated in the postpartum period, but no further recommendations are provided with 
respect to management of rubella risk during pregnancy.8 However, guidelines 
surrounding risk counseling and travel do seem to be within ACOG’s purview, as the 
organization recommends counseling surrounding air travel and avoidance of travel to 
areas with endemic transmission of hepatitis A, malaria, or Zika.8 
Risk Factors for Rubella and CRS 
In the U.S., international travel has been strongly associated with rubella and 
CRS. Since 2004, approximately ten cases of rubella have occurred in the U.S. each year, 
and all cases since 2012 have been associated with foreign travel.26,30 From 2005-2017, 
 7 
fifteen U.S.-born infants were diagnosed with CRS, and most were born to mothers 
known to have traveled during pregnancy.14 
I reviewed published case reports describing CRS diagnosed in infants born in the 
U.S. between 2004 and 2020 in order to identify risk factors for CRS in the post-
elimination period. Six reports describing eight CRS incidents diagnosed in the U.S. were 
identified.31-36 All but one case32 of CRS were born to women who had been born outside 
of the U.S. and either traveled internationally or lived outside of the U.S. during 
pregnancy. We therefore consider foreign birth, recent immigration to the U.S., and 
international travel as risk factors for CRS.  
Rubella Seroprevalence 
Immunization from rubella via vaccination or infection results in the production 
of virus-specific IgG antibodies, which persist in an immunized individual's serum for 
decades.37 Serological assays such as ELISA are useful for directly measuring 
susceptibility to rubella by quantifying the concentration of rubella antibodies in an 
individual’s blood. These quantities can be used to calculate the proportion susceptible 
when applied at the population level, giving a sense of the magnitude of infection risk 
experienced in the population of interest. Furthermore, the study of population-level 
immunity can be used to identify socio-demographic groups with comparatively lower 
levels of immunity.38 Several studies have estimated the prevalence of rubella 
susceptibility in the U.S. over time, but few have been conducted since the virus was 
eliminated and fewer still have estimated the proportion susceptible among women of 
reproductive age specifically. In general, the published literature does not consider socio-
demographic factors associated with travel for men and women separately and may mask 
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meaningful susceptibility differences within socio-demographic groups if these 
differences vary by sex. To our knowledge, no studies have estimated differences in 
seroprevalence among demographic groups considered likely to travel during pregnancy.  
Two studies have assessed seroprevalence of rubella antibodies among pregnant 
women. Bascom et al.39 assessed performance on recommended practices surrounding 
perinatal hepatitis B and rubella prevention at 25 hospitals located in New Hampshire. 
The authors evaluated rates of prenatal screening, patient seroprevalence, and the 
administration of vaccine before hospital discharge for rubella to non-immune women 
who delivered at the included hospitals. Records from patients delivering infants in 2000 
(n=2,021) were included in the analysis. The precise age range for patients was not 
reported but was theoretically between 10 and 54 years; 57% of patients were in the age 
range of 25-34 years. Among (n=2,008) women screened for rubella immunity, 6.7% 
were found susceptible. Susceptibility did not differ significantly by age, gravidity, nor 
parity in univariate analyses. However, interpretation of results from this study is 
difficult, as the laboratory methods used to measure antibody concentrations for rubella 
were not described in the patient record and were not presented in the publication. 
Immunity to rubella was assessed by the authors according to hand-written notes in the 
medical record categorizing lab results as immune, non-immune, or equivocal. Without 
knowledge of the antibody thresholds used to determine susceptibility, the ability to draw 
comparisons between this and other studies is limited. Moreover, the investigators did not 
consider patient characteristics other than age, parity, and gravidity as predictors for 
susceptibility; as such, few inferences can be made about susceptibility among women 
expected to travel. Finally, as the authors indicate, overall prevalence of rubella 
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susceptibility among women in this study may not reflect prevalence of U.S. women 
overall, as foreign born women are expected to have higher levels of susceptibility than 
women born domestically, and the population of foreign-born women in New Hampshire 
is relatively small compared to that in the U.S. as a whole.39 
Kennedy et al.40 evaluated antibody titers to rubella in their survey of serum 
samples from pregnant women in Iowa in order to test whether rubella immunity predicts 
mumps immunity. Serum samples (n=900) collected from pregnant women for routine 
antenatal screening between January and November 2004 were selected from those stored 
at the Iowa State Hygienic Laboratory. Immunity to rubella was assessed via a 
commercially available rubella IgG ELISA. Among the 785 samples for which women’s 
ages were known, average age was 28 years (range 14 to 44). The cutoff used to 
determine immunity was not described. Though the investigators estimated 
seroprevalence to rubella among a large sample of pregnant women falling within the age 
range typically considered reproductive, the study was not able to determine differences 
in susceptibility by socio-demographic characteristics, as data on characteristics other 
than age were not available to the investigators. Further limitations as they relate to our 
purposes were use of a sample specific to Iowa, whose demographic makeup may vary 
considerably from the total U.S. population and failure to report the threshold used to 
determine rubella immunity. 
A third study,41 also conducted in Iowa, evaluated susceptibility among women 
receiving prenatal care at a high-risk clinic in 2007. Serologic screening results from 641 
women were included in the analysis, among whom 44 (6.9%) were found seronegative. 
The specific age range of the sample was not provided, but when grouping women by age 
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categories defined as <20, 20-29, and >30, seronegativity to rubella was 10.2%, 6.2%, 
and 5.9%,respectively. Susceptibility was highest among Native Americans (17.3%), 
followed by white (7.3%), Black (5.9%), and Hispanic (4.6%) groups. In a univariate 
analysis and multivariate analysis adjusting for age, the difference between white and 
Native American groups was significant. The authors indicated that susceptibility to 
rubella may differ by age and race, but as statistical evaluations were reported for only 
race-ethnicity comparison, inferences about susceptibility by age or between other racial 
and ethnic groups cannot be made. In addition, individuals reporting Asian race or 
Somalian nationality were excluded from the study as well as those who identified as 
“other” race or ethnicity. 
In the only study emphasizing the risk of acquiring rubella during international 
travel, Rosario-Rosario et al.42 estimated seroprevalence of rubella by birth cohort in the 
Lehigh Valley Region using serum samples from individuals born prior to 1996. The goal 
of the study was to identify differences in susceptibility by age in order to identify groups 
at greatest risk of infection during travel. Samples were obtained from leftover outpatient 
serum samples taken between November 2013 and February 2014 at the Lehigh Valley 
Health Network. Antibodies to rubella were assessed using a commercially available 
enzyme immunoassay. The determination of immunity was made at a threshold of >10 
IU/mL. Participants with equivocal results (5-9 IU/mL) were excluded from the analysis. 
The authors found no significant differences by sex. When grouping the study sample 
into 10-year age cohorts starting with birth in the year 1957, a pattern of decreasing 
immunity with age was observed over the birth cohorts spanning the years 1967 to 1995 
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and increasing immunity with age over the remaining birth cohort groups.  However, 
differences in immunity between cohorts were not significant.  
Four rubella seroprevalence studies utilizing data from the National Health and 
Nutrition Examination Survey (NHANES), a survey enrolling a nationally representative 
sample of US residents, have been published since 2000. One study43 evaluated rubella 
seropositivity among participants from NHANES III, conducted from 1988 to 1994. 
Women of reproductive age in this study are not expected to be representative of women 
currently of reproductive age because rubella vaccination rates changed substantially 
during the 1990s,1 and rubella was eliminated from the U.S. in 2004. Accordingly, we did 
not review this study further.  
The remaining NHANES studies evaluated seroprevalence using an immunity 
threshold of >10 IU/mL, determined using an enzyme immunoassay. The second study 
was a report published by the National Center for Health Statistics.44 In this report, 
seroprevalence to rubella and other infectious diseases were estimated among NHANES 
respondents aged 6-49 years participating in the survey between 1999 and 2004. The 
authors compared data from Los Angeles county residents to that from the NHANES 
sample overall, finding that rubella seropositivity was approximately 91% in both groups; 
this finding was consistent across Mexican American respondents in both groups as well. 
Other socio-demographic variables were not considered.  
In a third study using NHANES data, Hyde et al.45 estimated seroprevalence of 
rubella antibodies, comparing these estimates across two time periods (1988-1994, 1999-
2004) in order to assess changes in seropositivity within demographic groups of interest 
and to evaluate whether immunity to rubella in the 1999-2004 survey exceeded the 
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elimination threshold of 87%. Separate analyses were carried out evaluating rubella 
susceptibility among school-age children (6-19 years) and adults of reproductive age (20-
49 years). The authors found that seropositivity for rubella was 91.5% among female 
NHANES 1999-2004 respondents.  
Lebo et al.46 conducted the most recent study estimating seroprevalence of 
antibodies to rubella using NHANES data. Using data from NHANES 2009-2010 for 
respondents aged 6-49 years, the authors estimated overall prevalence of rubella 
seropositivity and in several socio-demographic groups. Seropositivity was defined as 
rubella IgG ELISA II result of >10 IU/mL. Respondents in older age categories had 
significantly lower prevalence of rubella immunity than those aged 6-11 years. In 
reproductive aged groups, seropositivity was 96, 93, and 94% among participants aged 
20-29, 30-39, and 40-49 years, respectively. Female participants had significantly higher 
seroprevalence than men, and non-Hispanic black participants had significantly higher 
seroprevalence than white participants. No significant differences were found between 
Mexican Americans and white participants or between groups defined by U.S. and non-
U.S. place of birth. Using a large (n=5,054), nationally representative sample, this study 
provides evidence of differences in seroprevalence of rubella antibodies by age, sex, and 
ethnicity. However, differences by age and ethnicity were not evaluated by sex and 
susceptibility was, accordingly, not assessed by socio-demographic characteristics among 
women of reproductive age. 
Two studies estimated seroprevalence of rubella among military recruits. Eick et 
al.47 assessed immunity among a cohort of recruits enlisting in the U.S. Air Force, Army, 
Navy, or Marine Corps between January 2000 and December 2004. Demographic, 
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occupational, immunization, and medical data on recruits aged 17 to 35 years were 
extracted from the Defense Medical Surveillance System. The analysis included data 
from 3,000 subjects with serum specimens available for laboratory testing, which were 
selected to reflect the distribution of demographic characteristics among recruits to the 
U.S. military. Immunity to rubella was quantified using the Rubella Captia IgG ELISA, 
measuring an Immune Status Ratio (specimen optical density/calibrator optical density). 
Cutoff values for negative, equivocal, and positive results were < 0.90, 0.91-1.09, and 
>1.10, respectively. Equivocal results were considered negative for the purposes of 
analysis. Seronegativity was estimated at 5.2% in the sample overall, and 5.4% among 
females specifically. Odds of seropositivity were higher among recruits aged 30-35 as 
compared to those aged 17-19 years. White recruits had the lowest rates of seropositivity 
(93.3%), and seropositivity was significantly higher among black, Hispanic, and “other” 
race/ethnicity groups. In a subsample of the population that underwent targeted 
vaccination following sample collection, foreign-born recruits had higher odds of 
seropositivity than did U.S.-born recruits. Seropositivity did not vary significantly by 
education in years or by location of birth among the subsample that was subsequently 
universally vaccinated. This study provides evidence that immunity to rubella may differ 
by age, ethnicity, and place of birth, with white and foreign-born individuals more likely 
to be susceptible to infection, and older individuals more likely immune. The study 
sample fell within the range of reproductive age, though individuals aged 36 and older 
were not included. The finding that 5.6% of females are susceptible to rubella may not 
apply to the overall population of reproductive-aged women in the U.S. Furthermore, 
results may not apply on the national scale as the study included a group of military 
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recruits, which may comprise a specific, non-representative segment of the U.S. 
population.  
The second study including a sample of military recruits was performed by Lewis 
et al.48 The authors estimated seroprevalence in the total population of recruits and in 
groups categorized by age and sex using antibody titer data from all recruits to the U.S. 
Air Force who entered basic training between April 25, 2013 and April 24, 2014. The 
goal of the study was to determine whether seroprevalence of antibodies to measles, 
mumps, and rubella surpassed herd immunity thresholds. Rubella titers were estimated 
using the BioRad BioPlex 2200 MMRV IgG multiplex flow immunoassay, which 
allowed for the simultaneous measurements of antibodies to measles, mumps, and 
rubella. The titer threshold used to determine seropositivity was not reported. Among the 
sample overall (n = 32,502), rubella seroprevalence was 82%. Among females, this 
proportion was 86%, and was significantly higher than that observed among males, after 
adjusting for differences in age (OR 1.06, p = 0.007). Rubella varied from 81.6% in the 
age group 20-24 years to 86.5% in the age group 30-34 years. Prevalence of rubella 
immunity was significantly higher among recruits aged 30-34 (OR 1.05, 95%, p < 0.001) 
than those aged 17-19. This study demonstrates a small variation in rubella seropositivity 
by age among a population of military recruits. Though the study sample was likely of 
reproductive age, the upper bound for recruits was not provided. Like the study by Eick 
et al., the results from this study may not apply to the U.S. population of reproductive age 
if military recruits differ systematically from the U.S. population in terms of 
characteristics that predict rubella immunity. 
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Finally, Crooke et al.49 conducted a seroprevalence study to estimate population 
level immunity to rubella in Olmsted, MN and its surrounding municipalities. Immunity 
to rubella was measured for the overall study sample and within groups characterized by 
sex, age, and BMI quartile. Approximately 1,400 Mayo Clinic Biobank samples from 
participants aged between 20 and 44 years were included for analysis. IgG antibody titers 
to rubella virus were estimated using the Zeus Rubella IgG ELISA test. Individuals with 
titers > 10 IU/mL were considered rubella immune, while those between 8.19 and 9.99 
IU/mL were equivocal, and those below 8.19 IU/mL were considered susceptible. Dates 
of sample collection were not provided, but began in 2009.50 The biobank participants 
had a median age of 36.82 years (IQR: 32.55-40.81); 80.2% were female. Susceptibility 
to rubella was 2.2% in the sample overall, and women had a higher average titer to 
rubella than men. For the purposes of understanding differences in susceptibility to 
rubella among demographic groups, a weakness of this study is that it compared average 
titers between groups, rather than comparing the proportions considered immune. In 
addition, though the study included individuals who fell within the reproductive ages, the 
ages of participants did not span this category, which is defined by the WHO as ages 15-
49.51 With a mean age of about 37 years, participants were also older on average than the 
average reproductive age in the U.S.52 and a substantial portion would have been born 
prior to the introduction of RCVs, potentially making this sample a poor reflection of 
immunity among reproductive age women in the U.S. more recently.  
Objectives 
A woman’s chances of acquiring rubella infection and subsequently birthing an 
infant affected by CRS depends on both her rubella immunity status and her exposure to 
 16 
the rubella virus during pregnancy. Seroprevalence studies conducted shortly before or 
following rubella’s elimination from the U.S. indicate that immunity to the rubella virus  
may be related to age, foreign birth, race, and ethnicity,42,42,46-48 while case reports and 
surveillance data published in the post-elimination era suggest that rubella and CRS are 
associated with travel, foreign birth, and recent U.S. immigration.31,33-36 In order to 
identify groups at highest risk for CRS on a national scale, we evaluated the hypotheses 
that susceptibility to rubella is associated with age, foreign birth, race-ethnicity, foreign 
travel, and recent U.S. immigration. We defined susceptibility to rubella as an IgG titer 
below 10 IU/mL, as defined in several previous seroprevalence studies.   
As previously stated, a majority of CRS cases occurring in the U.S. over the past 
15 years have been born to mothers who recently traveled to or immigrated from foreign 
countries and endemic rubella transmission is known to continue in countries outside of 
the Americas. In the absence of travel advisories provided by health agencies such as 
WHO and CDC, women may unknowingly travel to areas with a high prevalence of 
rubella. Accordingly, a second objective was to identify countries where risk of rubella 
infection and CRS are the highest in order to highlight areas to which travel may be 
inadvisable during early pregnancy. We used a rubella transmission model, informed by 
previous work on rubella dynamics, to calculate the country-specific force of infection, 
defined as the rate at which susceptible individuals are infected, as a measure of rubella 
and CRS risk.  
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Methods 
The National Health and Nutrition Examination Survey 
 The source of data for this study was the National Health and Nutrition 
Examination Survey (NHANES), a series of cross-sectional surveys designed by the 
National Center for Health Statistics (NCHS) to assess the health and nutrition status of 
the U.S. population.52 The survey employs a stratified, multistage, probability-cluster 
design to generate a representative sample of the country’s civilian noninstitutionalized 
residents.52 Consecutive NHANES surveys are conducted in 2-year cycles, with 
approximately 5,000 people enrolled each year.52 In the 2009-2010 cycle, Hispanic and 
non-Hispanic black persons, low-income persons of non-Hispanic or “other” race, and 
adults aged 80 and over were oversampled to allow for precise health indicator estimates 
within these groups.4 Respondents answered a household interview that included 
demographic and household information and were asked to participate in an examination 
which involved assessment of several health measures as well as collection of blood and 
urine specimens for laboratory testing. The Institutional Review Board of the NCHS 
approved the study protocol.  
a. Laboratory Analysis  
 Serum samples collected from NHANES 2009-2010 respondents who participated 
in the exam portion of the study were tested for IgG antibodies to rubella using the 
Wampole Rubella IgG II ELISA. The laboratory assay procedures are described 
elsewhere.53 We defined non-immunity to rubella as <10 IU/mL based on the CDC’s 
recommendation that individuals with titers below this threshold be immunized 
regardless of their vaccination history.54 However, since serologic correlates of immunity 
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to rubella are not well understood, we also conducted a secondary analysis in which 
rubella susceptibility was defined as a titer at or below 8.18 IU/mL, as titers between 8.18 
and 10 IU/mL are considered equivocal for rubella immunity.53  The results of this 
analysis are displayed in the supplement (Tables S1 and S2). 
b. Statistical Analysis 
 We calculated prevalence of susceptibility to rubella in the participant sample 
overall and in several socio-demographic groups. Using univariate logistic regression 
models, we assessed the relative difference in odds of non-immunity comparing groups 
hypothesized to be at risk for CRS to those thought to be at lower risk. Regressions were 
performed for each of the following variables: age, race/ethnicity, birth outside the U.S., 
citizenship status, reported receipt of hepatitis A vaccine, and having lived in the U.S. for 
less than 10 years. All prevalence estimates and odds ratios were weighted to represent 
the U.S. civilian non-institutionalized population, accounting for NHANES oversampling 
and non-response to the household interview or physical exam.55 Standard errors were 
calculated using the Taylor series linearization method available through Stata version 15 
(StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp 
LLC). 
 Adult female participants of reproductive age (18-49 years) with rubella IgG 
laboratory results were included in the analysis. Demographic variables were collected 
during the household interview portion of the survey. Race and ethnicity were coded as 
non-Hispanic white, non-Hispanic Black, Hispanic, and other non-Hispanic. Hispanic 
ethnicity included women who reported being Mexican American or other Hispanic. 
Other, non-Hispanic race-ethnicity included women who reported non-Hispanic ethnicity 
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and race other than Black or white, including mixed race. Country of birth was coded as 
birth in the U.S. and birth outside of the U.S. Citizenship status was categorized as 
citizen, non-citizen, or don’t know/refused. Questions regarding international travel were 
not asked of NHANES participants. To assess the association between travel and rubella 
susceptibility, we performed a logistic regression categorizing individuals based on 
reported receipt of vaccination for hepatitis A, since travel is one indication for the 
vaccine in the U.S. Hepatitis A vaccination was assessed during the participant exam. 
Women who reported receiving at least one dose of the vaccine were categorized as such 
while those who stated they had not been vaccinated or were not sure were categorized as 
not reporting vaccination.  
 Participants who reported being born outside of the U.S. during the household 
questionnaire were asked a follow-up question regarding how long they have lived in the 
U.S. We hypothesized that individuals living in the U.S. for shorter periods have higher 
prevalence of susceptibility than individuals living in the U.S. for longer periods. To test 
this hypothesis, we conducted a subgroup analysis using logistic regression comparing 
women who had resided in the U.S. less than 10 years to those who lived in the U.S. 10 
years or more. Individuals who refused to answer or who reported not knowing how long 
they had lived in the U.S. were re-coded as missing and excluded from the sub analysis. 
Country-Specific Rubella Risk 
We used a discrete-time deterministic age-structured compartmental rubella 
transmission model to calculate country-specific estimates of risk for rubella infection, 
building from previous work describing rubella dynamics.56,57 This model defined 
transitions at each time step from every combination of  epidemiologic compartment (i.e., 
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maternally immune, susceptible, infected, recovered, and vaccinated) and age group 
(grouped into one month intervals up to 20 years old and 1 year intervals from 20 to 100 
years old) to every other possible combination of epidemiological stage and age group.  
We simulated rubella dynamics for all WHO member countries from 1980 to 
2020, with the exception of countries in the WHO Americas Region where rubella has 
been eliminated. Demographic parameters including population size, crude birth rates, 
and age-specific death rates were extracted from the United Nations Population Division 
estimates via the wpp2017 package. Routine and campaign associated rubella vaccination 
coverage were time- and country-specific; they were extracted from the WHO/UNICEF 
estimates of national immunization coverage from 1980 to 2020.58 Vaccination coverage 
was adjusted based on the assumptions that repeated vaccination activities are not 
completely independent and a portion of the population may always remain inaccessible 
to vaccination. Duration of maternal immunity and vaccine efficacy were assumed from 
published literature and are constant across time and country.  
The model output was annual age-specific force of infection. The country average 
force of infection was estimated by taking a weighted average of the age-specific 
estimates. We combined these estimates for each country, with country-specific travel 
data to calculate both risk of acquiring rubella infection and the expected number of 
infections among travelers each year, assuming an average travel duration of 2 weeks. 
Annual travel volume between the United States and other countries was estimated as the 
mean annual travel from 2017-2019, using full itinerary travel volume data from OAG 
(https://www.oag.com/).  Risk for infection for each country was calculated as the annual 
force of infection per 1,000 susceptible, multiplied by the number of annual travelers to 
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the country. Relative risk of infection was estimated as the country-specific risk divided 
by the mean risk for all countries included in the analysis. The expected number of 
infections was the number of annual travelers expected to be susceptible multiplied by 
the force of infection for a two-week period. Expectation of susceptibility (3%) was 
derived from our preceding analysis of NHANES serology data. Countries included in 
the analysis were located in any of the 5 WHO regions that have not yet eliminated 







Of the 1,836 female NHANES 2009-10 participants aged 18-49 years, 1,800 
completed both the household interview and the physical exam. Among these women, 
1,685 had lab results for IgG antibodies to rubella. Women excluded from the analysis 
based on absence of exam or rubella IgG data did not differ from women included on any 
variables in our analysis. 
Table 1 shows characteristics of the analytic sample by rubella susceptibility, 
weighted to represent the population of adult U.S. women of reproductive age. Overall, 
54 (3.3%, 95% CI:  2.3-4.7%) participants were seronegative for rubella. Susceptible 
participants were on average older than those who were immune, and were more likely to 
report white race, Hispanic ethnicity, and U.S. citizenship. In contrast, women who were 
rubella immune were more likely to report Black or other race, to be born outside the 
U.S. and receive at least one dose of hepatitis A vaccine.  
Rubella Susceptibility  
Table 2 shows the weighted prevalence of susceptibility to rubella within 
categories of socio-demographic variables, as well as univariable odds ratios estimating 
relative differences in susceptibility between comparison and referent groups for each 
variable. Distributions of rubella IgG antibodies by categories of each variable are 
displayed in figures 1-6.  
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The proportion susceptible to rubella within 5-year age categories ranged from 
0.82% for ages 18-19, to 7.24% for ages 40-44 years. Women aged 25-29 were selected 
as the referent group, as this age group had the highest rate of fertility in the U.S. during 
the study period.59 There were no significant differences between the referent and other 
age groups except that women aged 40-44 had a significantly higher odds of 
susceptibility.  
Susceptibility ranged from 0.86 to 4.04% among racial and ethnic groups, with 
the lowest proportion occurring in the group categorized as “other” (0.39%) and the 
highest proportion susceptible occurring among the group identifying as Hispanic 
(4.15%). White women were chosen as the referent group in our regression analysis. 
Odds ratios comparing Black (OR 0.59, 95% CI 0.22-1.60) and Hispanic (OR 1.12, 95% 
CI 0.55-2.27) racial groups to the referent group did not differ significantly. Women 
reporting other race had significantly lower odds of susceptibility as compared to white 
women (OR 0.10, 95% CI 0.01-0.85). 
For the variable defined as birth outside of the U.S., 3.52% and 2.49% of 
individuals were susceptible in the U.S.-born and foreign-born groups respectively; the 
relative odds of susceptibility comparing women born in the U.S. to those born elsewhere 
was not significant (OR 0.70, 95% CI 0.25-1.99). Similarly, odds of rubella susceptibility 
were not different between categories of citizenship status. The odds ratio comparing 
non-citizens to citizens was 0.53 (95% CI 0.20-1.35), while it was 2.36 (95% CI 0.20-
27.89) for women who refused to answer or did not know their citizenship status 
compared to citizens.  
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The proportion of susceptible individuals among women who reported receipt of 
at least one dose of hepatitis A vaccine was 3.85%, while it was 2.01% for those not 
reporting hepatitis A vaccination. Odds of susceptibility were not significantly different 
between the two groups (OR 0.51, 95% CI 0.23-1.22).  
Of 478 participants who reported being foreign-born, 441 provided data on 
number of years living in the U.S. Within this group, susceptibility to rubella was 3.31% 
overall. For the 274 participants who had lived in the U.S. for at least 10 years and the 
167 who had lived in the U.S. for 9 years or fewer, the respective prevalence of rubella 
susceptibility was 2.55% and 1.20% . The odds ratio of susceptibility (OR 0.46, 95% CI 
0.09-2.25) was not significantly different for the two groups. A multivariable analysis 
adjusting for differences in age between the two groups yielded similar insignificant 
results (OR 0.74, 95% CI 0.14-3.81). 
Transmission Model Results 
We estimated the force of rubella infection for 147 countries. Of these, only one 
country (Yemen) had no travel data available. Tables 3 and 4 display the 20 countries 
with the highest force of infection per 1,000 (FOI) and highest relative risks of infection, 
respectively. Country specific FOI estimates ranged from <0.001 to 85.3, with the highest 
estimated FOIs in countries in Africa. Forty-three countries had annual forces of infection 
estimated above one infection per 1,000 susceptible population. Among these countries, 
the median FOI was 57 infections (IQR 38-73).  
The median FOI was below 0.001 in each of the 5 WHO regions. However, the 
distributions of FOI varied substantially between regions (Figure 7). The African region 
(AFR) had the highest mean FOI at 26.3 (75th percentile: 70.9), and 16 (35%) of its 45 
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countries had FOIs above one. In the Eastern Mediterranean region (EMR) the mean FOI 
was 22.7 (75th percentile: 50.1), while in the European region (EUR), it was estimated to 
be 7.7 (75th percentile: 0.05). Mean FOI was estimated for the Western Pacific (WPR) at 
7.6 (75th percentile: 0.001) and for the Southeast Asia (SEAR) region at 6.5 (75th 
percentile: 3.4). In each respective regions EMR, EUR, WPR, and SEAR the percentage 
of countries with FOIs of at least one was 24, 38, 19, and 27%. 
Ordering of countries in terms of risk for rubella acquisition varied from the 
ordering based on FOI alone when accounting for volume of U.S. travel specific to each 
country. Travel from the U.S. to all countries totaled approximately 50 million trips, and 
the bulk of this travel was to EUR (56%) and WPR (29%). As such, countries located 
within these WHO regions were more heavily represented among countries with the 
highest probabilities of infection for U.S. travelers (Table 4; Figure 8). The expected 
annual number of infections among U.S. trips per country each year ranged from <0.001 
to 148, with 23 (16%) of included countries expecting at least 1 infection per year. 
However, when examining FOI by travel volume (Figure 9) there appears to be a trend of 
decreasing FOI with increasing travel, potentially indicating that travel to countries with 
the highest forces of infection is rare compared to countries with lower FOIs. 
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Discussion 
This study evaluated susceptibility to rubella among women of reproductive age 
in the time following elimination of endemic transmission of rubella in the U.S. Using an 
analysis of serological and survey data among the U.S. population, we found significant 
differences in rubella seroprevalence between women aged 40-44 years as compared to 
women aged 25-29, and between white women as compared to women reporting “other” 
non-Hispanic race-ethnicity. No other significant differences were observed comparing 
women expected to have higher rubella seroprevalence (via vaccination or natural 
infection) to those hypothesized to have lower rubella seroprevalence. In addition to our 
analysis of rubella seroprevalence by socio-demographic characteristics, we assessed the 
risk of infection for various countries using country-specific estimates of the annual force 
of infection derived from a rubella transmission model. We found that the rate of 
infection during a two-week travel period, given susceptibility, is high in several 
countries. 
On the national scale, this study suggests no particular risk factor that can be used 
for targeting clinical recommendations surrounding travel during pregnancy as they relate 
to rubella. This finding may be due to an absence of differences between socio-
demographic groups in the U.S., but may also be explained by other factors. The sample 
size of several groups in our study may not have been sufficient for detecting true 
differences in rubella non-immunity among these groups; seronegativity to rubella also 
was rare. In addition, the sampling strategy employed by the NHANES survey may not 
have captured groups at high risk for rubella susceptibility, such as unvaccinated refugees 
or religious and cultural groups that abstain from vaccination. Another possibility is that 
the data collected through NHANES were not granular enough to be able to identify 
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specific groups with higher proportions susceptible. For example, rubella immunity may 
vary by country of birth, but this data was available in four broad categories rather than 
by specific country.  Furthermore, national level data may have masked heterogeneity in 
rubella susceptibility at smaller spatial scales. 
Despite the lack of risk factors for rubella seroprevalence, our finding that 
approximately 3% of adult female U.S. residents of reproductive age are susceptible to 
rubella may be clinically important. Three percent of the female population of 
reproductive ages represents a substantial number of women (~ 2 million, and about 
120,000 women giving birth each year)60 potentially at risk for CRS, as women of 
reproductive age in the U.S. comprise a population of approximately 68 million.61 Based 
on this knowledge, we are not calling for a recommended end for travel to rubella 
endemic areas during pregnancy among women found susceptible, but rather are 
highlighting the need for discussions of risks associated with travel, and perhaps a 
recommendation of delaying travel until later in pregnancy, when risk of CRS is lower. 
Our analysis suggests that travel to areas with the highest forces of infection is 
relatively rare, as countries with the highest forces of infection are not necessarily those 
where the highest number of rubella cases are expected to occur (see Tables 3 and 4, 
Figure 10). This observation indicates that there is likely only a small proportion of U.S.-
resident women who are at considerable risk for prenatal rubella infection. In addition, 
countries with the highest forces of rubella infection are located in regions where rubella 
vaccination rates are low or rubella vaccine has not been introduced into the childhood 
immunization schedule,19 meaning women who were born in these countries before 
immigrating to the U.S. may not have been vaccinated nor infected, depending on the age 
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at which they emigrated. These women may represent a group at particularly high risk, as 
they may also be more likely to return to their countries of birth for purposes such as 
visiting family members.62 
This study had several limitations. Participants in the NHANES survey were aged 
18-49 years in 2009-2010. The two older age groups were born prior to or shortly 
following the licensing of rubella vaccine in the U.S., and as such, their levels of 
susceptibility may not be representative of women in these age ranges today. More 
specifically, women in the age category 40-44 years had lower immunity than other age 
groups, which may be an artifact of the implementation of the rubella vaccine rollout 
since this group may have been less likely to be vaccinated than younger age groups, but 
also less likely than the oldest age group to have acquired natural immunity through 
infection. Moreover, vaccination rates may also differ between the current time period 
and 2009-2010. However, because NHANES no longer collected rubella antibody data 
following its 2009-2010 cycle, more recent data could not be collected from this source.  
 Travel is associated with risk for CRS as most cases occurring in the past 15 years 
have occurred subsequent to travel or immigration from a foreign country. It is therefore 
important to measure prevalence of susceptibility among demographic groups expected to 
travel, especially among those who are expected to travel to countries with endemic 
rubella transmission. We were not able to identify a direct measure of travel in the 
publicly available NHANES datasets, and used hepatitis A vaccination status as its proxy, 
since travel is one indication for the vaccine. However, it is also possible that this vaccine 
is more commonly administered to those who travel and are from higher SES groups, or 
who otherwise have better access to healthcare and are thus more likely to have been 
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adequately vaccinated against rubella. Our finding that individuals who were vaccinated 
from hepatitis A had a higher seroprevalence of rubella supports this hypothesis. 
Our analysis of country-level risk for rubella infection had several limitations as 
well. The force of infection assumes that the proportion of infectious individuals in a 
country overall is equal to the proportion of infectious individuals with whom a traveler 
comes into contact, and that the probability of infection is constant across all contacts 
with infectives. These assumptions may be violated if social mixing is not uniform across 
susceptible and immune travelers, or if infection probabilities per contact vary across 
these groups as well. For example, susceptible women may travel to visit family 
members living in the country and share closer quarters with infectious individuals, while 
immune individuals may be more likely to travel for business or leisure purposes and 
only come into contact with infectives in public. By applying the proportion susceptible 
to rubella for the U.S. overall to our estimates of expected infections per country, we 
assume that the probability of travel is equal among susceptible and immune individuals 
and that the ratio of susceptible to immune travelers does not vary by country. However, 
this assumption may not hold if immune status is related to likelihood of travel. For 
example, we may underestimate the expected number of infections acquired in a country 
if the proportion of travelers susceptible is higher than that observed in the U.S. 
population overall. Additionally, the transmission model used to estimate the force of 
infection for each country relies on potentially biased data to estimate epidemiological 
and demographic input parameters, and makes many assumptions about transmission 
patterns across the country that will likely bias results, but in unknown directions.  For 
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example, the model does not allow for spatial demographic and epidemiologic 
heterogeneities and assumes homogenous spatial mixing across the entire country. 
Based on the limitations of our study, future research may include larger numbers 
of participants in order to achieve adequate power for making assessments of national 
level data. In addition, research should focus on capturing some granularity in socio-
demographic measures that is missed by NHANES. Seroprevalence studies conducted at 
smaller spatial scales (e.g., counties, cities, hospitals) may detect important differences in 
susceptibility based on the particular demographic makeup of the target population that 








 We provide evidence that approximately 3% of the population of reproductive 
aged women in the U.S. are susceptible to rubella, translating to roughly 2 million 
women potentially at risk. The force of infection in some rubella endemic countries 
remains high, and as such, women expected to travel to endemic areas comprise a group 
that may be at especially high risk for infection. Though rubella and CRS are rare in the 
U.S. overall, risk should be reduced to the furthest extent possible given that 
consequences of maternal infection during pregnancy can be severely damaging to the 
fetus. The finding that a large number of women of reproductive age are potentially 
susceptible to infection indicates a role for a revision of travel guidelines to help reduce 
individual-level risk for CRS. On the basis of the high probability of infection estimated 
for countries with endemic rubella transmission, future research should focus on 




Tables and Figures 
 
Table 1. Participant characteristics, by rubella susceptibility (IgG <10 IU/mL) 
Characteristic Susceptible  Immune 
 Na Proportion ± SE (%)b  Na Proportion ± SE (%)b  
Overall (N) 54 3.3 ± 0.56  1631 96.7 ± 0.56 
Age (years)      
18-19 2 1.3  ±  0.9  124 5.3 ± 0.7 
20-24 7 17.3 ± 8.3  255 14.5 ± 1.0 
25-29 6 8.9 ± 4.7  242 16.2 ± 0.9 
30-34 6 10.8 ± 3.9  240 14.8 ± 1.2 
35-39 8 10.5 ± 4.0  242 15.5 ± 1.2 
40-44 19 39.5 ± 6.4  265 17.3 ± 1.1 
45-49 6 11.7 ± 5.2  263 16.4 ± 1.5 
Race/ethnicity      
White 25 68.5 ± 9.2  706 60.5 ± 4.1 
Black 6 9.0 ± 4.0  288 13.4 ± 1.1 
Hispanic 22 21.5 ± 8.6  522 17.1 ± 3.1 
Other 1 1.0 ± 1.0  115 9.0 ± 1.4 
Born outside of the 
US 11 15.3 ± 6.1  467 20.5 ± 2.6 
Citizenship status      
Citizen 46 92.4 ± 3.2  1325 87.5 ± 1.9 
Not a citizen 7 6.8 ± 3.1  301 12.2 ± 1.9 
Refused/Unknown 1 0.8 ± 0.8  5 0.3 ± 0.2 
Received hepatitis A 
vaccine 12 17.6 ± 6.3  518 29.5 ± 1.5 
Abbreviations: SE, standard error. 
a. N: unweighted number of respondents. 




Table 2. Prevalence and univariable odds ratios of rubella susceptibility (IgG <10 IU/mL) 




Prevalence ± SE 
(%) a 
 
OR (95% CI) a 
Age group, years    
18-19  126 0.82 ± 0.62 0.43 (0.07-2.73) 
20-24 262 3.94 ± 1.97 2.18 (0.33-14.57) 
25-29 248 1.85 ± 0.90 Ref 
30-34 246 2.45 ± 0.90 1.33 (0.36-4.89) 
35-39 250 2.28 ± 1.05 1.24 (0.24-6.38) 
40-44 284 7.24 ± 1.86 4.14 (1.11-15.52)b 
45-49 269 2.39 ± 1.15 1.3 (0.30-5.59) 
Race/ethnicity    
White 731 3.73 ± 0.86 Ref 
Black 294 2.24 ± 0.85 0.59 (0.22-1.60) 
Hispanic 544 4.15 ± 1.01 1.12 (0.55-2.27) 
Other 116 0.39 ± 0.39 0.1 (0.01-0.85) b 
Country of birth    
U.S.  1207 3.52 ± 0.62 Ref 
Outside of the U.S. 478 2.49 ± 1.13 0.70 (0.25-1.99) 
Citizenship status    
Citizen 1371 3.50 ± 0.62 Ref 
Not a citizen 308 1.87 ± 0.76 0.53 (0.20-1.35) 
Refused/Unknown 6 7.87 ± 8.32 2.36 (0.20-27.89) 
Received hepatitis A 
vaccine    
No 1155 3.85 ± 0.69 Ref 
Yes 530 2.01 ± 0.76 0.51 (0.23-1.22) 
Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval; Ref, reference group. 
a. NHANES survey weights applied to represent the total U.S. noninstitutionalized population. Accounts for 
oversampling and non-response. 





Figure 1. Distribution of rubella IgG antibodies by age  
 
 
This figure displays the distribution of rubella IgG antibody concentrations by age among 
NHANES respondents. Respondents aged 40-44 years in 2009-2010 were found to have 
significantly higher odds of susceptibility to rubella as compared to those aged 25-29. 
However, the median rubella titer is generally similar across age groups, with a slight 
increasing trend in the median with increasing age.  
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Figure 2. Distribution of rubella IgG antibodies by race-ethnicity 
 
 
This figure displays the distribution of rubella IgG antibody concentrations across racial 
and ethnic groups reported by NHANES 2009-2010 respondents. In our weighted 
analysis, women reporting “other” race-ethnicity had lower odds of rubella susceptibility 
than women reporting white, non-Hispanic race-ethnicity (OR , 95% CI ). Here, the full 
distribution of titers shows that the smallest variations in IgG titer occurred among 
individuals reporting Black, non-Hispanic race. Most titers are above the 10 IU/mL 
threshold for immunity, and the median titers is approximately equal across racial and 




Figure 3. Distribution of rubella IgG antibodies by location of birth. 
 
Foreign birth was considered a risk factor for rubella susceptibility, as the rubella vaccine 
is not available in all countries, and most CRS births in the U.S. since 2004 were to 
mothers born outside the U.S. This figure shows that among NHANES respondents, 
foreign-born women had higher IgG titers to rubella than women born in the U.S. Our 
analysis showed that women born in foreign countries had lower odds of susceptibility as 
compared to women in the U.S., however, odds did not vary significantly between the 
two groups. The higher titer observed among foreign born women could possibly be 
attributable to higher rates of natural infection, which is expected to induce a stronger 
antibody response as compared to vaccination. 
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Figure 4. Distribution of rubella IgG antibodies by citizenship status. 
 
In NHANES 2009-2010, women who reported non-citizenship to the U.S. had lower 
odds of susceptibility than women who reported U.S. citizenship. Women who refused or 
did not know their citizenship status also had lower odds of susceptibility. Odds ratios for 
both comparisons were not significant. This figure shows the distributions of rubella IgG 
titers for each group. Median antibody titers are higher for the non-citizen and refused/did 
not know group. Similar to the observations made with respect to women born in the U.S. 
as compared to those born outside the U.S., women who are not citizens may have had 






Figure 5. Distribution of rubella IgG antibodies by reported receipt of hepatitis A 
vaccine. 
 
We hypothesized that women reporting hepatitis A vaccination in NHANES 2009-2010 
would have higher odds of susceptibility to rubella. Rubella A vaccination status was 
used as a proxy for travel, since foreign travel is on indication for the vaccine. However, 
odds of susceptibility were not significantly different between the two groups. This figure 
illustrates that the distributions of antibody titers are very similar between those who are 




Figure 6. Distribution of rubella IgG antibodies and age by length of time living in the 
U.S. 
 
This figure shows the age and rubella antibody distributions for women who had lived in 
the U.S. for 10 years or more and those who had lived in the U.S. for less than 10 years. 
We hypothesized that immunity to rubella would be lower among women who had lived 
in the U.S. for a shorter duration, but found no significant differences in odds of 
susceptibility. Age distributions are displayed here to demonstrate whether differences in 
susceptibility by duration of U.S. residence may be driven by differences in age. As 
expected, women who have lived in the U.S. for at least 10 years are older than those 










Travelers FOIa  Riskb RRc 
Expected 
Infectionsd 
Niger AFR 5,656 85.3 482.6 0.30 0.56 
Guinea-Bissau AFR 532 84.2 44.8 0.03 0.05 
Guinea AFR 12,122 81.7 990.7 0.61 1.14 
Mali AFR 7,981 81.4 649.7 0.40 0.75 
Chad AFR 4,627 80.9 374.5 0.23 0.43 
Somalia EMR 6,321 80.1 506.2 0.31 0.58 
Democratic Republic of 
the Congo AFR 15,173 79.7 1208.9 0.74 1.39 
Central African Republic AFR 1,878 75.6 142.0 0.09 0.16 
Congo AFR 4,040 75.3 304.0 0.19 0.35 
Liberia AFR 18,071 74.5 1345.7 0.83 1.55 
Nigeria AFR 285,900 73.9 21124.5 13.01 24.37 
Equatorial Guinea AFR 10,013 73.4 735.4 0.45 0.85 
Comoros AFR 275 71.0 19.5 0.01 0.02 
Sudan EMR 23,880 70.8 1691.4 1.04 1.95 
Ethiopia AFR 115,950 68.9 7993.0 4.92 9.22 
Madagascar AFR 6,667 67.5 450.0 0.28 0.52 
Kyrgyzstan EUR 20,917 63.5 1328.5 0.82 1.53 
Iraq EMR 64,787 63.3 4101.9 2.53 4.73 
Afghanistan EMR 24,979 63.3 1581.2 0.97 1.82 
Georgia EUR 39,416 58.6 2308.7 1.42 2.66 
a. Annual force of infection per 1,000 susceptible, estimated from rubella transmission model. 
b. Country-level risk for infection among all U.S. based travelers, equal to FOI * annual number of travelers. 
c. Relative risk for infection, equal to country-specific risk/mean risk for all countries. 










Travelers FOIa Riskb RRc 
Expected 
Infectionsd 
China WPR 3,861,091 0.03 128,594 79.20 148.38 
Nigeria AFR 285,900 0.07 21,124 13.01 24.37 
South Africa AFR 334,986 0.06 19,083 11.75 22.02 
Pakistan EMR 285,993 0.05 14,727 9.07 16.99 
Ethiopia AFR 115,950 0.07 7,993 4.92 9.22 
Ukraine EUR 213,962 0.03 7,311 4.50 8.44 
Iraq EMR 64,787 0.06 4,102 2.53 4.73 
Serbia EUR 87,130 0.04 3,340 2.06 3.85 
Armenia EUR 64,531 0.05 3,144 1.94 3.63 
Albania EUR 69,950 0.03 2,436 1.50 2.81 
Georgia EUR 39,416 0.06 2,309 1.42 2.66 
Thailand SEAR 623,315 0.00 2,106 1.30 2.43 
Sri Lanka SEAR 56,534 0.04 2,025 1.25 2.34 
Sudan EMR 23,880 0.07 1,691 1.04 1.95 
Afghanistan EMR 24,979 0.06 1,581 0.97 1.82 
Belarus EUR 35,057 0.04 1,371 0.84 1.58 
Liberia AFR 18,071 0.07 1,346 0.83 1.55 
Kyrgyzstan EUR 20,917 0.06 1,328 0.82 1.53 
Tunisia EMR 26,108 0.05 1,250 0.77 1.44 
Democratic Republic of 
the Congo AFR 15,173 0.08 1,209 0.74 1.39 
a. Annual force of infection per 1,000 susceptible, estimated from rubella transmission model. 
b. Country-level risk for infection among all U.S. based travelers, equal to FOI * annual number of travelers. 
c. Relative risk for infection, equal to country-specific risk/mean risk for all countries. 
d. Expected infections among U.S. based travelers, equal to risk * proportion susceptible to rubella. 
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Figure 7. Distribution of rubella force of infection in countries located within WHO 
regions with endemic transmission.
 
The force of rubella infection varies substantially over the 5 WHO regions that have not 
yet eliminated rubella. The highest FOIs occur in the African and Eastern Mediterranean 
Regions, indicating that given susceptibility, the probability of infection is highest in 









Risk for rubella infection was calculated as the number of travelers to a particular country 
multiplied by the country-specific force of infection for rubella. The relative risk 
compares risk across countries by dividing the country-specific risk by the mean risk for 
all countries. In relative terms, risk of infection is highest in China, followed by Nigeria, 
South Africa, and Pakistan. Countries in each of the 5 WHO regions studied have 




Figure 9. Country-level annual force of infection by travel volume from the U.S. 
 
This scatterplot shows the country-level force of infection by log travel volume coming 
from the U.S. A lowess curve is included to explore the trend in the force of infection 











Table S1. Participant characteristics, by alternative measure of rubella susceptibility (IgG 
<8.18 IU/mL). 
Characteristic Susceptible  Immune 
 Na 
Proportion ± SE 
(%)b  Na 
Proportion ± SE 
(%)b 
Overall (N) 37 2.2 ± 0.4  1,648 97.8 ± 0.4 
Age (years)      
18-19 1 0.9 ± 0.9  125 5.3 ±  0.7 
20-24 4 14.4 ± 10.4  258 14.6 ± 1.1 
25-29 4 10.6 ± 6.7  244 16.1 ± 0.9 
30-34 3 8.1 ± 3.1  243 14.8 ± 1.2 
35-39 6 9.2 ± 4.6  244 15.5 ± 1.2 
40-44 13 39.4 ± 9.1  271 17.6 ± 1.1 
45-49 6 17.5 ± 7.6  263 16.2 ± 1.5 
Race/ethnicity      
White 16 67.5 ± 9.2  715 60.6 ± 4.1 
Black 3 6.0 ± 3.6  291 13.4 ± 1.2 
Hispanic 17 25.0 ± 9.4  527 17.0 ± 3.1 
Other 1 1.5 ± 1.5  115 8.9 ± 1.4 
Born outside of the US 11 23.0 ± 8.6  467 20.2 ± 2.6 
Citizenship status      
Citizen 29 88.6 ± 4.6  1,342 87.6 ± 1.9 
Not a citizen 7 10.2 ± 4.5  301 12.1 ± 1.9 
Refused/Unknown 1 1.2 ± 1.2  5 0.3 ± 0.2 
Received hepatitis A 
vaccine 8 29.3 ± 1.6  522 19.0 ± 7.1 
Abbreviations: SE, standard error. 
a. N: unweighted number of respondents. 













Table S2. Prevalence and univariable odds ratios of alternative measure of rubella 




(N) Prevalence ± SE (%) a 
 
OR (95% CI) a 
Age group, years    
18-19  126 0.38 ± 0.38 0.25 (0.21-3.14) 
20-24 262 2.18 ± 1.64 1.50 (0.10-22.37) 
25-29 248 1.46 ± 0.84 Ref 
30-34 246 1.21 ± 0.41 0.83 (0.19-3.65) 
35-39 250 1.32 ± 0.72 0.90 (0.16-4.97) 
40-44 284 4.81 ± 1.52 3.42 (0.69-16.92) 
45-49 269 2.39 ± 1.15 1.65 (0.33-8.17) 
Race/ethnicity    
White 731 2.45 ± 0.51 Ref 
Black 294 1.00 ± 0.60 0.4 (0.11-1.48) 
Hispanic 544 3.20 ± 0.87 1.32 (0.68-2.54) 
Other 116 0.39 ± 0.39 0.16 (0.02-1.26) 
Country of birth    
U.S.  1,181 2.13 ± 0.39 Ref 
Outside of the U.S. 467 2.49 ± 1.13 1.17 (0.39-3.54) 
Citizenship status    
Citizen 1,342 2.23 ± 0.41 Ref 
Not a citizen 301 1.87 ± 0.76 0.84 (0.32-2.20) 
Refused/Unknown 5 7.87 ± 8.32 3.74 (0.30-45.99) 
Received hepatitis A 
vaccine    
No 1,155 2.52 ± 0.40 Ref 
Yes 530 1.44 ± 0.64 0.56 (0.22-1.47) 
Abbreviations: SE, standard error, OR, odds ratio; CI, confidence interval; Ref, reference group. 
a. NHANES survey weights applied to represent the total U.S. noninstitutionalized population. Accounts for 
oversampling and non-response. 
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